Villablanca Eduardo J, Zhou Dan, Valentinis Barbara, Negro Aurora, Raccosta Laura, Mauri Laura, Prinetti Alessandro, Sonnino Sandro, Bordignon Claudio, Traversari Catia, Russo Vincenzo
Cancer Gene Therapy Unit, Cancer Immunotherapy and Gene Therapy Program, Scientific Institute H. San Raffaele, Milan, Italy.
J Leukoc Biol. 2008 Sep;84(3):871-9. doi: 10.1189/jlb.0108047. Epub 2008 May 30.
Dendritic cell (DC) migration to secondary lymphoid organs is a crucial step to initiate adaptive immune responses. This step requires the expression of a functional CCR7 chemokine receptor on DC undergoing maturation. Here, we show that the natural retinoid 9-cis retinoic acid (9cRA) and the synthetic retinoid fenretinide (4-HPR) specifically inhibit the functional up-regulation of CCR7 on maturing human DCs, without affecting early steps of DC maturation. As a consequence, mature DCs do not migrate in vitro toward the chemokine CCL19. Importantly, 4-HPR and 9cRA by inhibiting the expression of CCR7 on bone marrow-derived murine DCs dampen their in vivo migration to draining lymph nodes. 4-HPR also inhibits the expression of the chemokine receptors CXCR4, therefore, impairing in vitro migration of human DCs to CXCL12 and inhibiting in vivo the CXCR4-dependent migration of the posterior lateral line primordium (PLLp) in zebrafish embryos. Taken together, these data highlight a novel function of retinoids and suggest the possibility of using retinoids to treat inflammatory or autoimmune diseases.
树突状细胞(DC)迁移至次级淋巴器官是启动适应性免疫反应的关键步骤。这一步骤要求正在成熟的DC表达功能性趋化因子受体CCR7。在此,我们发现天然类视黄醇9-顺式视黄酸(9cRA)和合成类视黄醇芬维A胺(4-HPR)能特异性抑制成熟人DC上CCR7的功能性上调,而不影响DC成熟的早期步骤。结果,成熟DC在体外不会向趋化因子CCL19迁移。重要的是,4-HPR和9cRA通过抑制骨髓来源的鼠DC上CCR7的表达,减弱其在体内向引流淋巴结的迁移。4-HPR还抑制趋化因子受体CXCR4的表达,因此,损害人DC在体外向CXCL12的迁移,并在体内抑制斑马鱼胚胎后侧线原基(PLLp)的CXCR4依赖性迁移。综上所述,这些数据突出了类视黄醇的一种新功能,并提示使用类视黄醇治疗炎症性或自身免疫性疾病的可能性。